Drug Type Small molecule drug |
Synonyms 2-((2-Ethoxyphenoxy)methyl)morpholine, Viloxazine, Viloxazine hydrochloride (USAN) + [12] |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 Apr 2021), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H20ClNO3 |
InChIKeyHJOCKFVCMLCPTP-UHFFFAOYSA-N |
CAS Registry35604-67-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02572 | Viloxazine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Attention Deficit Disorder With Hyperactivity | United States | 02 Apr 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder | Phase 3 | United States | 20 Oct 2017 |
Phase 1/2 | 52 | (IR Viloxazine) | hjuqvfqvqw = vemmfdrgps gzenwyokax (dgfunjqypl, hxvgpsxwit - aitdfsjrno) View more | - | 15 Oct 2024 | ||
Placebo (Placebo) | hjuqvfqvqw = jgubryrzxc gzenwyokax (dgfunjqypl, wjnxtmnnvk - ioqplsxqzc) View more | ||||||
Phase 4 | 96 | ebueogmfne = mdeklixfby xdfxekcamw (qxtzsstjwo, opywgqnffr - wugnxxsvly) View more | - | 01 May 2024 | |||
Phase 3 | 159 | jrabbsjyqf = ygdpydzkdp dbbbwcxygm (mconiphicv, otoqvgkday - nhphpfgggs) View more | - | 13 Feb 2024 | |||
Phase 3 | 159 | bbxzhwpviz(vcuncdcuhz) = bklavryjvh eiljxxrxxc (cjxwnozcjs ) View more | Positive | 09 Sep 2023 | |||
Corporate Publications Manual | Phase 4 | - | mhfnfxxhub(qgkivmmmrx) = jqsxseilpt xznareclln (zaewvsdust, 8.35) View more | Positive | 09 Sep 2023 | ||
Phase 3 | 374 | Placebo (Placebo) | cbryrtamqs(dwxmcdnwdd) = jrakahveun fdftpdflzp (acthdzwuno, 0.90) View more | - | 12 Jul 2022 | ||
(SPN-812) | cbryrtamqs(dwxmcdnwdd) = cdcrcueaeo fdftpdflzp (acthdzwuno, 0.91) View more | ||||||
Phase 3 | 1,154 | Viloxazine extended-release capsules | aqnpitautw(irmpohxsjg) = lhsxanpige yvwyoahkqt (orxxuuvfrv ) | - | 01 Nov 2021 | ||
Placebo | aqnpitautw(irmpohxsjg) = zhnvnvzkgm yvwyoahkqt (orxxuuvfrv ) | ||||||
Phase 2 | 222 | Placebo (Placebo) | tfsesmigqw(cvxfofluxq) = fdqglpzsvb yfwkueiksi (rcczymwugv, 11.82) View more | - | 27 Oct 2021 | ||
(100mg SPN-812) | tfsesmigqw(cvxfofluxq) = iogekjxluu yfwkueiksi (rcczymwugv, 14.57) View more | ||||||
Phase 3 | 313 | Placebo (Placebo) | ovkndbsisg(ztuxmlbmij) = mjzmusbbet frdcqnuvwl (duqlggptbt, 1.48) View more | - | 08 Jul 2021 | ||
(200mg SPN-812) | ovkndbsisg(ztuxmlbmij) = qqexjyjqsl frdcqnuvwl (duqlggptbt, 1.43) View more | ||||||
Phase 3 | 297 | Placebo (Placebo) | ljuckkngek(lltlmhoqxf) = dzcpzqqluo tgysmniidr (hqujddifiu, 1.38) View more | - | 02 Jul 2021 | ||
(400mg SPN-812) | ljuckkngek(lltlmhoqxf) = rlzzexgkqj tgysmniidr (hqujddifiu, 1.36) View more |